Everolimus plus immunotherapy for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs—everolimus, which may slow cancer growth, and a PD-1 inhibitor, which helps the immune system fight cancer—for people with advanced colorectal cancer that has progressed after standard treatments. The goal is to see if the combination can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced colorectal cancer that cannot be fully removed with surgery.
- Your cancer has grown or you couldn't tolerate standard treatments like fluorouracil, irinotecan, or oxaliplatin.
- Your tumor has a PTEN mutation.
- You are in generally good health (able to care for yourself, ECOG 0-1).
- You have at least one measurable tumor on imaging.
- Your blood counts and organ function are within acceptable ranges for the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding rimegepant (a migraine drug) to a PD-1 inhibitor (a type of immunotherapy) can help patients with colorectal cancer that has spread to the liver. The goal is to see if this combination can slow down the cancer or shrink tumors.
This trial tests whether adding digoxin, a heart medication, to standard chemotherapy and an immunotherapy drug can help people with advanced colorectal cancer that has not responded to previous treatments. The goal is to see if this combination shrinks tumors or slows the cancer's growth.
This trial tests a drug called everolimus for people with advanced colorectal cancer that has a specific change in a gene called CDK12. It aims to see if this drug can slow down the cancer when other treatments have stopped working.
This study tests a new combination of drugs, including an immunotherapy and a targeted therapy, for colorectal cancer that has spread. The goal is to see if this combination can help shrink tumors or slow the cancer. It is designed for people who have not yet received treatment for metastatic disease.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new combination of high and low-dose radiation with immunotherapy and a targeted drug for advanced colorectal cancer that has not responded to previous treatments. The goal is to see if this approach can help shrink tumors and improve outcomes.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.